Floatz Rating
B56/100
Confidence
Indicative
Sponsor
InxMed (Shanghai) Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05982522CT.gov IN10018 Combination Therapy in Previously-treated Solid Tumors | — | Withdrawn | — | — | — |
NCT06977828CT.gov A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06487858CT.gov A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors | — | Terminated | — | — | — |
NCT06349837CT.gov Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors | — | Recruiting | — | — | — |
NCT05644626CT.gov Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants | — | Withdrawn | — | — | — |
NCT05981703CT.gov A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05935098CT.gov BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT05798533CT.gov Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | — | Unknown | — | — | — |
NCT05581719CT.gov A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | — | Terminated | — | — | — |
NCT05494762CT.gov Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
Show 7 more trialsShow fewer
NCT05833984CT.gov Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | — | Unknown | — | — | — |
NCT05167071CT.gov HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | — | Active Not Recruiting | — | — | — |
NCT05097781CT.gov Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | — | Unknown | — | — | — |
NCT04666688CT.gov LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04261439CT.gov A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | — | Terminated | — | — | — |
NCT02660034CT.gov The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00395434CT.gov Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tislelizumab (this asset) | InxMed (Shanghai) Co., Ltd. | P2 | B · 56 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Tislelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 69 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
| Classic Hodgkin Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tislelizumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tislelizumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →